Mondego Bio Launches First Clinical Trial of Cancer Treatment Advancing Immunotherapy Strategies
Mondego Bio, a promising player in the biotechnology landscape, has officially kicked off its first-in-human Phase 1 clinical study for MB‑388, an innovative oral dual inhibitor targeting PTPN2 and PTPN1. This groundbreaking research is designed to tackle one of the most significant challenges in cancer treatment today: the resistance faced by patients undergoing immunotherapy. The Phase 1a component of the trial will involve healthy volunteers, as the team seeks to meticulously evaluate the safety and tolerability of MB‑388, along with its pharmacokinetic profile and engagement of relevant biological pathways.
The establishment of this study is particularly noteworthy as it employs a randomized, double-blind, placebo-controlled design, which underscores the commitment to rigorous scientific methodology. Participants will receive varying doses of MB‑388 to define parameters related to drug exposure and overall safety. Initial clinical investigation is anticipated to yield important pharmacodynamic (PD) biomarker data, establishing a foundation for future phases.
Several preclinical studies have hinted at the potential effectiveness of MB‑388 in real-world scenarios. Early results demonstrate that this dual inhibitor not only works effectively when used alone but also significantly enhances the efficacy of anti-PD-1 treatments. By improving immune responses—like increasing the presence of CD8-positive T cells and levels of granzyme B—MB‑388 may optimize outcomes for patients who remain resistant to conventional therapies.
Nikolay Savchuk, PhD, the CEO of Mondego Bio, articulated the importance of this phase of development. He stated, "Initiating the first clinical study of MB‑388 is an important milestone for Mondego. This Phase 1a study aims to firmly establish the relationship between drug exposure, pathway engagement, and patient tolerability, ultimately paving the way for our planned Phase 1b trial involving cancer patients."
Looking ahead, Mondego plans to transition into Phase 1b by January 2027, directing its focus onto patients dealing with advanced solid tumors who have seen no success with standard therapeutic approaches. The initial aim will be to assess MB‑388's performance as a monotherapy before exploring the possibility of combining it with PD-(L)1 blockade therapy—a strategy that could vastly improve treatment options for an underserved patient demographic. This latter part of the study will encompass both individuals who have not previously received checkpoint inhibitors and those who have.
The anticipation surrounding the outcome of this clinical trial is bolstered by the significant data expected to emerge over the coming months, including initial pharmacokinetic (PK) and PD findings slated for December 2026. Furthermore, updates on the combination treatment's dose escalation are anticipated in December 2027, setting the stage for intensive scrutiny of MB‑388's clinical utility.
Mondego Bio has roots in Portugal and prides itself on developing small-molecule therapies that aim to surmount barriers to effective cancer immunotherapy. Founded with the financial backing of notable investors—such as OrbiMed and Torrey Pines Investment—the company’s innovation-driven approach to immuno-oncology starkly highlights a commitment to enhancing patient outcomes in oncology. With MB‑388 at the forefront of its pipeline, Mondego Bio remains hopeful that its efforts will materially transform the landscape of cancer treatment, potentially setting new benchmarks in immunotherapy effectiveness.
In sum, as MB‑388 embarks on its clinical journey, it represents both a beacon of hope for many cancer patients and a key point of interest for the broader field of oncology research. Stakeholders from academia to industry await the forthcoming data, adeptly conveying their aspirations for advancements that may fundamentally reshape therapeutic strategies against cancer.
The establishment of this study is particularly noteworthy as it employs a randomized, double-blind, placebo-controlled design, which underscores the commitment to rigorous scientific methodology. Participants will receive varying doses of MB‑388 to define parameters related to drug exposure and overall safety. Initial clinical investigation is anticipated to yield important pharmacodynamic (PD) biomarker data, establishing a foundation for future phases.
Several preclinical studies have hinted at the potential effectiveness of MB‑388 in real-world scenarios. Early results demonstrate that this dual inhibitor not only works effectively when used alone but also significantly enhances the efficacy of anti-PD-1 treatments. By improving immune responses—like increasing the presence of CD8-positive T cells and levels of granzyme B—MB‑388 may optimize outcomes for patients who remain resistant to conventional therapies.
Nikolay Savchuk, PhD, the CEO of Mondego Bio, articulated the importance of this phase of development. He stated, "Initiating the first clinical study of MB‑388 is an important milestone for Mondego. This Phase 1a study aims to firmly establish the relationship between drug exposure, pathway engagement, and patient tolerability, ultimately paving the way for our planned Phase 1b trial involving cancer patients."
Looking ahead, Mondego plans to transition into Phase 1b by January 2027, directing its focus onto patients dealing with advanced solid tumors who have seen no success with standard therapeutic approaches. The initial aim will be to assess MB‑388's performance as a monotherapy before exploring the possibility of combining it with PD-(L)1 blockade therapy—a strategy that could vastly improve treatment options for an underserved patient demographic. This latter part of the study will encompass both individuals who have not previously received checkpoint inhibitors and those who have.
The anticipation surrounding the outcome of this clinical trial is bolstered by the significant data expected to emerge over the coming months, including initial pharmacokinetic (PK) and PD findings slated for December 2026. Furthermore, updates on the combination treatment's dose escalation are anticipated in December 2027, setting the stage for intensive scrutiny of MB‑388's clinical utility.
Mondego Bio has roots in Portugal and prides itself on developing small-molecule therapies that aim to surmount barriers to effective cancer immunotherapy. Founded with the financial backing of notable investors—such as OrbiMed and Torrey Pines Investment—the company’s innovation-driven approach to immuno-oncology starkly highlights a commitment to enhancing patient outcomes in oncology. With MB‑388 at the forefront of its pipeline, Mondego Bio remains hopeful that its efforts will materially transform the landscape of cancer treatment, potentially setting new benchmarks in immunotherapy effectiveness.
In sum, as MB‑388 embarks on its clinical journey, it represents both a beacon of hope for many cancer patients and a key point of interest for the broader field of oncology research. Stakeholders from academia to industry await the forthcoming data, adeptly conveying their aspirations for advancements that may fundamentally reshape therapeutic strategies against cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.